The association between PD-L2 expression and survival outcome has been investigated in several malignancies, including CRC, melanoma, pancreatic cancer, and esophageal cancer33,38–41; however, discrepancies between these studies have been observed. This evidence concerns the gene PDCD1LG2 and melanoma.